Runsheng Wang1, Sherine E Gabriel2, Michael M Ward1. 1. National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland. 2. Mayo Clinic, Rochester, Minnesota.
Abstract
OBJECTIVE: The long-term outcome of patients with nonradiographic axial spondyloarthritis (SpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective was to examine the progression to AS in a population-based inception cohort of patients with nonradiographic axial SpA. METHODS: The Rochester Epidemiology Project (REP) is a longstanding population-based study of health in the residents of Olmsted County, Minnesota. We searched the REP from 1985 to 2010 using diagnostic and procedural codes for back pain, HLA-B27, and magnetic resonance imaging of the pelvis, and we performed detailed chart reviews to identify subjects who fulfilled the Assessment of SpondyloArthritis international Society classification criteria for axial SpA but did not have AS. We followed these subjects from disease onset to March 15, 2015, and used survival analysis to measure the time to progression to AS. RESULTS: After screening 2,151 patients, we identified 83 subjects with new-onset nonradiographic axial SpA. Over a mean follow-up of 10.6 years, progression to AS occurred in 16 patients. The probability that the condition would remain as nonradiographic axial SpA at 5, 10, and 15 years was 93.6%, 82.7%, and 73.6%, respectively. There was more frequent and more rapid progression among subjects in the imaging arm (n = 18) than among those in the clinical arm (n = 65) (28% versus 17%; hazard ratio 3.50 [95% confidence interval 1.15-10.6], P = 0.02). CONCLUSION: Progression to AS occurred in a minority (26%) of patients with nonradiographic axial SpA over as long as 15 years of follow-up. This suggests that the classification criteria for nonradiographic axial SpA identifies many patients in whom the condition is unlikely to progress to AS or that nonradiographic axial SpA represents a prolonged prodromal state that takes longer to evolve to AS and thus requires longer follow-up.
OBJECTIVE: The long-term outcome of patients with nonradiographic axial spondyloarthritis (SpA) is unclear, particularly whether few or most progress to ankylosing spondylitis (AS). Our objective was to examine the progression to AS in a population-based inception cohort of patients with nonradiographic axial SpA. METHODS: The Rochester Epidemiology Project (REP) is a longstanding population-based study of health in the residents of Olmsted County, Minnesota. We searched the REP from 1985 to 2010 using diagnostic and procedural codes for back pain, HLA-B27, and magnetic resonance imaging of the pelvis, and we performed detailed chart reviews to identify subjects who fulfilled the Assessment of SpondyloArthritis international Society classification criteria for axial SpA but did not have AS. We followed these subjects from disease onset to March 15, 2015, and used survival analysis to measure the time to progression to AS. RESULTS: After screening 2,151 patients, we identified 83 subjects with new-onset nonradiographic axial SpA. Over a mean follow-up of 10.6 years, progression to AS occurred in 16 patients. The probability that the condition would remain as nonradiographic axial SpA at 5, 10, and 15 years was 93.6%, 82.7%, and 73.6%, respectively. There was more frequent and more rapid progression among subjects in the imaging arm (n = 18) than among those in the clinical arm (n = 65) (28% versus 17%; hazard ratio 3.50 [95% confidence interval 1.15-10.6], P = 0.02). CONCLUSION: Progression to AS occurred in a minority (26%) of patients with nonradiographic axial SpA over as long as 15 years of follow-up. This suggests that the classification criteria for nonradiographic axial SpA identifies many patients in whom the condition is unlikely to progress to AS or that nonradiographic axial SpA represents a prolonged prodromal state that takes longer to evolve to AS and thus requires longer follow-up.
Authors: Atul Deodhar; John D Reveille; Filip van den Bosch; Jürgen Braun; Ruben Burgos-Vargas; Liron Caplan; Daniel O Clegg; Robert A Colbert; Lianne S Gensler; Désirée van der Heijde; Irene E van der Horst-Bruinsma; Robert D Inman; Walter P Maksymowych; Philip J Mease; Siba Raychaudhuri; Andreas Reimold; Martin Rudwaleit; Joachim Sieper; Michael H Weisman; Robert B M Landewé Journal: Arthritis Rheumatol Date: 2014-10 Impact factor: 10.995
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Anna Moltó; Simon Paternotte; Désirée van der Heijde; Pascal Claudepierre; Martin Rudwaleit; Maxime Dougados Journal: Ann Rheum Dis Date: 2014-01-03 Impact factor: 19.103
Authors: M van Onna; A G Jurik; D van der Heijde; A van Tubergen; L Heuft-Dorenbosch; R Landewé Journal: Ann Rheum Dis Date: 2011-08-22 Impact factor: 19.103
Authors: Sjef van der Linden; Nurullah Akkoc; Matthew A Brown; Philip C Robinson; Muhammad A Khan Journal: Curr Rheumatol Rep Date: 2015-09 Impact factor: 4.592
Authors: A Troldborg; S Thiel; C E Mistegaard; A Hansen; T-L Korsholm; K Stengaard-Pedersen; A G Loft Journal: Clin Exp Immunol Date: 2019-10-01 Impact factor: 4.330
Authors: Marina Magrey; Sergio Schwartzman; Natasha de Peyrecave; Victor S Sloan; Jeffrey L Stark Journal: Medicine (Baltimore) Date: 2022-04-15 Impact factor: 1.817
Authors: U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking Journal: Z Rheumatol Date: 2019-12 Impact factor: 1.372
Authors: Maxime Dougados; Christophe Demattei; Rosaline van den Berg; Viet Vo Hoang; Fabrice Thevenin; Monique Reijnierse; Damien Loeuille; Antoine Feydy; Pascal Claudepierre; Désirée van der Heijde Journal: Arthritis Rheumatol Date: 2016-08 Impact factor: 10.995